Identification of potential immune evasion mechanisms in aggressive small renal cell carcinomas through single-cell and bulk RNA sequencing. This is an ASCO Meeting Abstract from the 2025 ASCO ...

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy. Postsurgical immunotherapy significantly ...

Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled trial, ...

ITM-94, a gallium-68-radiolabeled PET imaging agent, targets carbonic anhydrase IX, crucial in tumor growth and metastasis. The FDA's fast track designation aims to expedite ITM-94's development for ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients with advanced clear cell ovarian and endometrial cancers who received ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...